Composite Survival Index to Compare Virulence Changes in Azole-Resistant Aspergillus fumigatus Clinical Isolates

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Mavridou, Eleftheria ^a   Meletiadis, Joseph ^b   Jancura, Pavol ^d   Abbas, Saiden ^d   Arendrup, Maiken C ^c   Melchers, Willem J G ^a   Heskes, Tom ^d   Mouton, Johan W ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c STATENS SERUM INSTITUT   (Denmark)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; COMPOSITE SURVIVAL INDEX; CONTROLLED STUDY; CYP51A GENE; FEMALE; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS ISOLATION; GENE; GENE MUTATION; GROWTH RATE; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; MATHEMATICAL MODEL; MOUSE; NONHUMAN; SCORING SYSTEM; SURVIVAL;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; AZOLES; CLUSTER ANALYSIS; MICROBIAL SENSITIVITY TESTS; VIRULENCE;

EID: 84883122490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072280     Document Type: Article

References (47)

1. Capilla J, Clemons KV, Stevens DA, (2007) Animal models: an important tool in mycology. Med Mycol 45: 657-684.
2. Tekaia F, Latge JP, (2005) Aspergillus fumigatus: saprophyte or pathogen? Curr Opin Microbiol 8: 385-392.
3. Clemons KV, Stevens DA, (2006) Gilead (2006) Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them? Med Mycol 44: 119-126.
4. Willger SD, Grahl N, Cramer RA Jr, (2009) Aspergillus fumigatus metabolism: clues to mechanisms of in vivo fungal growth and virulence. Med Mycol 47Suppl 1: S72-79.
5. Braga PC, Sasso MD, Sala MT, (2000) Sub-MIC concentrations of cefodizime interfere with various factors affecting bacterial virulence. J Antimicrob Chemother 45: 15-25.
6. Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF, (2011) Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother 55: 3254-3260.
7. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, et al. (1997) Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 41: 1364-1368.
8. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, et al. (2008) Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5: e219.
9. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ, (2009) Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet 9: 789-795.
10. van der Linden JWM, Jansen RR, Bresters D, Visser CE, Geerlings SE, et al. (2009) Azole-Resistant Central Nervous System Aspergillosis. Clin Infect Dis 48: 1111.
11. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE, (2007) Aspergillosis-and a misleading sensitivity result. Lancet 370: 102.
12. Howard SJ, Cerar D, Anderson MJ, Albarrag A, (2009) Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15: 1068-1076.
13. Verweij PE, Mellado E, Melchers WJ, (2007) Multiple-triazole-resistant aspergillosis. N Engl J Med 356: 1481-1483.
14. van der Linden JWM, Snelders E, Kampinga GA, Rijnders BJA, Mattsson E, et al. (2011) Spread and clinical impact of azole-resistance in Aspergillus fumigatus. Emerg Infect Dis 17: 1846-1854.
15. Willger SD, Puttikamonkul S, Kim KH, Burritt JB, Grahl N, et al. (2008) A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog 4: e1000200.
16. Chang YC, Bien CM, Lee H, Espenshade PJ, Kwon-Chung KJ, (2007) Sre1p, a regulator of oxygen sensing and sterol homeostasis, is required for virulence in Cryptococcus neoformans. Mol Microbiol 64: 614-629.
17. Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Moller N,et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5: e10080.
18. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL, (2001) Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 39: 2431-2438.
19. Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, et al. (2003) Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother 47: 577-581.
20. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL, (2004) Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 48: 2747-2750.
21. Nascimento AM, Goldman GH, Park S, Marras SAE, Delmas G, et al. (2003) Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole. Antimicrob Agents Chemother 47: 1719-1726.
22. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE, (2010) Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 54: 860-865.
23. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW, (2010) Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 54: 4758-4764.
24. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, et al. (2011) Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 17: 1846-1854.
25. Mondon P, De Champs C, Donadille A, Ambroise-Thomas P, Grillot R, (1996) Variation in virulence of Aspergillus fumigatus strains in a murine model of invasive pulmonary aspergillosis. J Med Microbiol 45: 186-191.
26. Clemons KV, Stevens DA, (2005) The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol 43Suppl 1: S101-110.
27. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, et al. (2011) Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 55: 4465-4468.
28. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, et al. (2012) Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 67: 362-366.
29. Mortensen KL, Mellado E, Lass-Florl C, Rodriguez-Tudela JL, Johansen HK, et al. (2010) Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 54: 4545-4549.
30. Snelders E, Huis In't Veld RA, Rijs AJ, Kema GH, Melchers WJ, et al. (2009) Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 75: 4053-4057.
31. de Valk HA, Meis JF, Curfs IM, Muehlethaler K, Mouton JW, et al. (2005) Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol 43: 4112-4120.
32. Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Lopez JF, Grimalt JO, et al. (2008) Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids 73: 339-347.
33. Clinical Committee for Clinical Laboratory S (2002) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A: National Committee for Clinical Laboratory Standards, Wayne, PA.
34. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, et al. (2001) Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 39: 3402-3408.
35. Meletiadis J, te Dorsthorst DT, Verweij PE, (2003) Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi. J Clinic microbiol 41: 4718-4725.
36. Pringle A, Taylor J, (2002) The fitness of filamentous fungi. Trends Microbiol 10: 474-481.
37. Meletiadis J, Meis JF, Mouton JW, Verweij PE, (2001) Analysis of growth characteristics of filamentous fungi in different nutrient media. J Clin Microbiol 39: 478-484.
38. Stevens JP, editor (1992) Applied multivariate statistics for the social sciences (Hillsdale, NJ: Erlbaum.).
39. Verweij PE, Howard SJ, Melchers WJ, Denning DW, (2009) Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 12: 141-147.
40. Camps SM, Dutilh BE, Arendrup MC, Rijs AJ, Snelders E, et al. (2012) Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One 7: e50034.
41. Schrettl M, Beckmann N, Varga J, Heinekamp T, Jacobsen ID, et al. (2010) HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatus. PLoS Pathog 6: e1001124.
42. Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A, (2011) Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J 30: 533-534.
43. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, et al. (2009) Azole-resistant central nervous system aspergillosis. Clin Infect Dis 48: 1111-1113.
44. Aimanianda V, Bayry J, Bozza S, Kniemeyer O, Perruccio K, et al. (2009) Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 460: 1117-1121.
45. Ng TT, Robson GD, Denning DW, (1994) Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140 (Pt 9): 2475-2479.
46. Thomas SR, Elkinton JS, (2004) Pathogenicity and virulence. J Invertebr Pathol 85: 146-151.
47. McClelland EE, Bernhardt P, Casadevall A, (2006) Estimating the relative contributions of virulence factors for pathogenic microbes. Infect Immun 74: 1500-1504.